Janus Henderson Group PLC Increases Position in Enanta Pharmaceuticals, Inc. $ENTA

Janus Henderson Group PLC lifted its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 1.5% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,784,055 shares of the biotechnology company’s stock after acquiring an additional 54,396 shares during the period. Janus Henderson Group PLC owned 13.01% of Enanta Pharmaceuticals worth $47,717,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. acquired a new stake in Enanta Pharmaceuticals during the 4th quarter worth about $32,000. Seven Fleet Capital Management LP acquired a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at about $36,000. Strs Ohio purchased a new position in shares of Enanta Pharmaceuticals in the fourth quarter worth about $50,000. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Enanta Pharmaceuticals by 333.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,584 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 2,758 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Enanta Pharmaceuticals during the third quarter worth about $81,000. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Finally, Wall Street Zen cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Enanta Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $20.29.

Enanta Pharmaceuticals Stock Down 3.1%

Shares of ENTA stock opened at $12.60 on Friday. The stock has a market cap of $366.41 million, a PE ratio of -4.86 and a beta of 0.96. The business has a 50-day simple moving average of $13.09 and a 200-day simple moving average of $13.41. Enanta Pharmaceuticals, Inc. has a 52-week low of $6.45 and a 52-week high of $17.15.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, May 11th. The biotechnology company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.01. The firm had revenue of $17.16 million for the quarter, compared to the consensus estimate of $17.03 million. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%. Sell-side analysts anticipate that Enanta Pharmaceuticals, Inc. will post -1.79 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.